65 related articles for article (PubMed ID: 30114869)
1. Human papillomavirus testing as part of the renewed National Cervical Screening Program.
Hawkes D
Aust J Gen Pract; 2018 Jul; 47(7):412-414. PubMed ID: 30114869
[TBL] [Abstract][Full Text] [Related]
2. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program.
Lew JB; Simms KT; Smith MA; Hall M; Kang YJ; Xu XM; Caruana M; Velentzis LS; Bessell T; Saville M; Hammond I; Canfell K
Lancet Public Health; 2017 Feb; 2(2):e96-e107. PubMed ID: 29253402
[TBL] [Abstract][Full Text] [Related]
3. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
[TBL] [Abstract][Full Text] [Related]
4. Cervical cancer prevention in Australia: Planning for the future.
Saville AM
Cancer Cytopathol; 2016 Apr; 124(4):235-40. PubMed ID: 26619381
[TBL] [Abstract][Full Text] [Related]
5. The rationale for implementation of HPV testing in routine cervical screening in Romania.
Iancu LS; Ursu RG
Rev Med Chir Soc Med Nat Iasi; 2013; 117(2):293-6. PubMed ID: 24340506
[No Abstract] [Full Text] [Related]
6. Clinical validation of REALQUALITY RQ-HPV Screen according to the international guidelines for human papillomavirus DNA test requirements for cervical screening.
Iacobellis M; Violante C; Notarachille G; Simone A; Scarfì R; Giuffrè G
Virol J; 2018 Mar; 15(1):48. PubMed ID: 29558950
[TBL] [Abstract][Full Text] [Related]
7. Transitioning from cytology-based screening to HPV-based screening at longer intervals: implications for resource use.
Smith MA; Gertig D; Hall M; Simms K; Lew JB; Malloy M; Saville M; Canfell K
BMC Health Serv Res; 2016 Apr; 16():147. PubMed ID: 27112193
[TBL] [Abstract][Full Text] [Related]
8. HPV testing and vaccination in Europe.
Leeson SC; Alibegashvili T; Arbyn M; Bergeron C; Carriero C; Mergui JL; Nieminen P; Prendiville W; Redman CW; Rieck GC; Quaas J; Petry KU
J Low Genit Tract Dis; 2014 Jan; 18(1):61-9. PubMed ID: 23774078
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the clinical performance of restriction fragment mass polymorphism (RFMP) and Roche linear array HPV test assays for HPV detection and genotyping.
Lee HP; Cho W; Bae JM; Shin JY; Shin SK; Hwang SY; Min KT; Kim SN; Lee SJ; Kim SO; Yoo WD; Hong SP
J Clin Virol; 2013 Jun; 57(2):130-5. PubMed ID: 23410688
[TBL] [Abstract][Full Text] [Related]
10. HPV detection methods and genotyping techniques in screening for cervical cancer.
Eide ML; Debaque H
Ann Pathol; 2012 Dec; 32(6):e15-23, 401-9. PubMed ID: 23244480
[TBL] [Abstract][Full Text] [Related]
11. [Investigation of HPV-DNA in cervical smear samples by two different methods: MY09/11 consensus PCR and type-specific real-time PCR].
Sahiner F; Gümral R; Sener K; Yiğit N; Dede M; Yapar M; Kubar A
Mikrobiyol Bul; 2012 Oct; 46(4):624-36. PubMed ID: 23188576
[TBL] [Abstract][Full Text] [Related]
12. Validation of intra- and inter-laboratory reproducibility of the Xpert HPV assay according to the international guidelines for cervical cancer screening.
Akbari A; Vanden Broeck D; Benoy I; Padalko E; Bogers J; Arbyn M
Virol J; 2018 Oct; 15(1):166. PubMed ID: 30373616
[TBL] [Abstract][Full Text] [Related]
13. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST).
Mayrand MH; Duarte-Franco E; Coutlée F; Rodrigues I; Walter SD; Ratnam S; Franco EL;
Int J Cancer; 2006 Aug; 119(3):615-23. PubMed ID: 16572425
[TBL] [Abstract][Full Text] [Related]
14. History, development and future of cancer screening in Australia.
Olver IN; Roder D
Public Health Res Pract; 2017 Jul; 27(3):. PubMed ID: 28765858
[TBL] [Abstract][Full Text] [Related]
15. Immediate biopsy of cervical cytology-negative and non-HPV-16/18 oncogenic types positive patients.
Karaca İ; Öztürk M; Comba C; Demirayak G; Alay İ; Erdoğan VŞ; Hoşgören M; Yaşar L
Diagn Cytopathol; 2018 Apr; 46(4):326-330. PubMed ID: 29460502
[TBL] [Abstract][Full Text] [Related]
16. Improving diagnostic capability for HPV disease internationally within the NIH-NIAID Division of AIDS Clinical Trial Networks.
Godfrey CC; Michelow PM; Godard M; Sahasrabuddhe VV; Darden J; Firnhaber CS; Wetherall NT; Bremer J; Coombs RW; Wilkin T;
Am J Clin Pathol; 2013 Dec; 140(6):881-9. PubMed ID: 24225757
[TBL] [Abstract][Full Text] [Related]
17. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial.
Lazcano-Ponce E; Lorincz AT; Cruz-Valdez A; Salmerón J; Uribe P; Velasco-Mondragón E; Nevarez PH; Acosta RD; Hernández-Avila M
Lancet; 2011 Nov; 378(9806):1868-73. PubMed ID: 22051739
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with human papillomavirus (HPV) test acceptability in primary screening for cervical cancer: A mixed methods research synthesis.
Tatar O; Thompson E; Naz A; Perez S; Shapiro GK; Wade K; Zimet G; Gilca V; Janda M; Kahn J; Daley E; Rosberger Z
Prev Med; 2018 Nov; 116():40-50. PubMed ID: 30172799
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of multiple primary and combination screening strategies in postmenopausal women for detection of cervical cancer in China.
Holt HK; Zhang L; Zhao FH; Hu SY; Zhao XL; Zhang X; Pan QJ; Zhang WH; Smith JS; Qiao YL
Int J Cancer; 2017 Feb; 140(3):544-554. PubMed ID: 27727464
[TBL] [Abstract][Full Text] [Related]
20. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.
Cuzick J; Arbyn M; Sankaranarayanan R; Tsu V; Ronco G; Mayrand MH; Dillner J; Meijer CJ
Vaccine; 2008 Aug; 26 Suppl 10():K29-41. PubMed ID: 18847555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
